drugset
Drugs / BGF MDI
last change Nov 2020 re-read 9 days ago

BGF MDI

also known as BGF · budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler · budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler · PT010
Investigated by
Pearl Therapeutics, Inc.

Trials 1

today NCT01980615 · Ph 1
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01980615 Nov → Dec 2013 — Pearl Therapeutics, Inc. Completed Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2019-10-01 AstraZeneca Update on US regulatory review of PT010 in COPD astrazeneca.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BGF MDI “The budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) is an inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist...” PMID 29544728 ↗ Mar 2018
Known as BGF ClinicalTrials.gov intervention name — accepted as the source's own label NCT01980615 ↗
Known as budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler “The Phase III KRONOS study (NCT02497001) found the fixed-dose combination triple therapy budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) to be...” PMID 33152467 ↗ Nov 2020
Known as budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler “The budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) is an inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist...” PMID 29544728 ↗ Mar 2018
Known as PT010 “Inhaled BGF (PT010) Dose 1” NCT01980615 ↗
Route Inhaled “Inhaled BGF (PT010) Dose 1” NCT01980615 ↗